In view of the observation that despite effective in saving many lives, availability of current post-exposure prophylaxis is poor in many rabies-endemic countries due to high costs, poor access, and supply, researchers developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. Post-exposure prophylaxis use was modelled according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. From 2020 to 2035 under the status quo, an occurrence of over 1 million deaths is estimated in the 67 countries considered. Post-exposure prophylaxis would avert 1,388,000 deaths (ie, an additional 489,000 deaths) and 68,010,000 disability-adjusted life-years (DALYs) over this time period. This improvement in access is noted to be highly cost-effective at only $635 per death averted and $33 per DALYs averted and is identified feasible under current vaccine production with a switch to economical intradermal regimens through a Gavi investment.